Recent Content
- (no title)
- Vyriad targets 2026 clinical trial for new experimental cell therapy VV169
- Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma
- Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA’s conclusions from the evaluation of 38 suspected cases
- Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
- (no title)
- Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy
- Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation
- Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
- Author Correction: Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma